AstraZeneca’s COPD therapy gets US FDA approval
April 26, 2016Research and Development, Sales and Marketing AstraZeneca, COPD, US FDA, drug approval
UK drug firm AstraZeneca (LSE: AZN) said the US Food and Drug Administration has approved its therapy to treat chronic …
Allergan breaks ground on $200 million expansion at Texas site
April 26, 2016Manufacturing and Production Allergan, doubling, expansion, eye care, facility, investment, manufacturing, size, texas, waco
Allergan (NYSE: AGN) has broken ground on a $200 million expansion at its manufacturing facility in Waco, Texas. The expansion …
Novartis exploring almost $14-billion stake sale in Roche – reports
April 26, 2016Manufacturing and Production, Sales and Marketing Financial, Merger & Acquisition, Novartis, Roche, Stake sale
Swiss pharma firm Novartis (VTX: NOVN) maybe looking at options to sell its one-third stake in cancer drugmaker Roche’s (VTX: …
EU grants approval for Gilead’s HIV treatment Descovy
April 26, 2016Manufacturing and Production, Research and Development EU, HIV, approval, descovy, taf
Gilead Sciences (NASDAQ: GILD) has announced that the fixed-dose combination HIV treatment, Descovy (emtricitabine, tenofovir alafenamide), has been granted marketing …
Valeant names Joseph Papa as new chief executive officer
April 25, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Chairman, Valeant, joseph papa, new, new ceo, papa, pearson
Valeant Pharmaceuticals has announced that Joseph C. Papa will succeed Michael Pearson as chairman and chief executive officer of the …
FDA, WHO criticise integrity of data at contract research firm Semler
April 25, 2016Research and Development, Sales and Marketing FDA, India, WHO, World Health Organisation, semler, semler research
The US Food and Drug Administration and the World Health Organisation have raised serious concerns related to violations of good …
Weekly Movers: PTC Therapeutics, Celator Pharmaceuticals, Chiasma, Sarepta and more…
April 25, 2016Research and Development, Sales and Marketing
With the earnings season in full swing this week investors focussed on the impact on stock moves as companies declared …
Pfizer, GSK’s anti-smoking drugs not linked to increase in serious neuropsychiatric adverse events – Study
April 25, 2016Research and Development, Sales and Marketing
Pharma giant Pfizer’s (NYSE: PFE) smoking cessation drug Chantix (varenicline) did not show an increase in serious neuropsychiatric adverse events …
Valeant receives further default notices due to its delayed 10-K filing
April 25, 2016Medical Communications, Sales and Marketing Valeant, default, risk, trouble, worry
Valeant Pharmaceuticals has issued a statement detailing that they have received additional notices of default under indentures due to its …
Merck’s colorectal cancer drug meets primary endpoint in Phase III study
April 25, 2016Research and Development, Sales and Marketing Erbitux, Merck, Serono, cancer drugs, colorectal cancer, increased survival, oncology, phase 3, phase III
Merck (FWB: MRK) has announced that its Phase III clinical trial of Erbitux, in combination with Folfox, met its primary …
AstraZeneca to sequence genomes to develop new drugs
April 22, 2016Medical Communications, Sales and Marketing AstraZeneca, Finland, Wellcome Trust, collaboration, genome, genomics, human longevity, institute for molecular medicine, sanger institute
AstraZeneca (LSE: AZN) has announced an integrated genomics initiative that aims to transform the drug discovery and development across is …
AbbVie announces further industry and academic collaborations
April 22, 2016Medical Communications, Research and Development AbbVie, collaboration, commercialisation, cytomx, partnership, research, university of chicago
AbbVie (NYSE: ABBV) has announced further collaborations that will see it partner with industry and academia to develop oncology candidates …
Biogen Q1 profits rise boosted by Tecfidera sales
April 22, 2016Medical Communications, Sales and Marketing Biogen, Q1, biotech, earnings, results, tecfidera
Shares in Biogen (Nasdaq: BIIB) climbed to close up over 5% Thursday after the company reported 18% rise in first-quarter …
Novartis muscular drug fails in Phase III trials
April 22, 2016Medical Communications, Research and Development FDA, Novartis, bimagrumab, breakthrough, morphosys, muscular, phase III
A muscular drug developed by Novartis (NYSE: NVS), in partnership with MorphoSys (ETR: MOR), failed to meet its primary endpoint …
Actelion ups outlook for 2016, reports Q1 net income up 12%
April 22, 2016Medical Communications, Sales and Marketing Actelion, Biotechnology, Q1 results, earnings, outlook
Swiss biotech company Actelion (VTX: ATLN) raised its outlook for 2016 and reported a 12% rise in first quarter net …
A win for Sanofi on Jevtana after NICE reverses guidance
April 22, 2016Medical Communications, Sales and Marketing Cancer Drugs Fund, Jevtana, NICE, Sanofi, recommendation, reversal
Prostate cancer treatment Jevtana (cabazitaxel), marketed by Sanofi (NYSE: SNY) has been recommended by NICE in its final guidance. The …
Bluebird Bio gene therapy posts encouraging results in treatment of rare brain disease
April 21, 2016Medical Communications, Research and Development Bluebird Bio, Phase II, gene therapy, lenti-d, paediatric, phase 2, phase 3, phase III, rare brain disease
Bluebird bio (NASDAQ: BLUE) has announced positive interim data from a Phase II/III trial evaluating their Lenti-D gene therapy in …
PCI Pharma Services’ Ian Parsonage to Share Serialization Expertise at Global Track & Trace Conference
April 21, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ian parsonage, pci pharma, serialisation
Ian Parsonage, Senior Director of Global Serialization for leading pharmaceutical services provider PCI Pharma Services, will present at the Global …
Shares plunge at Sarepta after negative FDA review on muscle disorder drug
April 21, 2016Research and Development, Sales and Marketing FDA, Sarepta Therapeutics, Shares, dive, fall, negative, plunge, sarepta
Sarepta Therapeutics (NASDAQ: SPRT) is counting the cost as shares plunge following a negative review given by staff at the …
GW Pharma’s cannabis-based epilepsy drug granted orphan designation by FDA
April 21, 2016Research and Development, Sales and Marketing GW Pharma, cannabis, cannabis-based, epilepsy
GW Pharmaceuticals (NASDAQ: GWPH) has announced that the US Food and Drug Administration has granted its cannabis-based epilepsy drug, Epidiolex …
Latest content
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
Alcami appoints Will Isom to lead laboratory services sales
